Eli Lilly
As on 01 Oct, 2025 | 01:29 IST
| Open | 728.28 |
| Previous Close | 726.51 |
| Beta | 0.37 |
| High | 766.35 |
| Low | 724.02 |
| TTM EPS See historical trend | 16.15(+77.67% YoY) |
| 52 Week High | 935.37 |
| 52 Week Low | 623.99 |
| TTM PE See historical trend | 47.21(Low PE) |
| Mkt. Cap ($ Billion) | 724.94 |
| Dividend Yield | 0.74 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 733.95 |
| 10 | 744.7 |
| 20 | 746.16 |
| 50 | 734.1 |
| 100 | 750.28 |
| 200 | 783.14 |
Returns
| 1 Week | 2.08% | |
| 1 Month | 4.08% | |
| 3 Months | -2.21% | |
| YTD | -1.16% | |
| 1 Year | -13.90% | |
| 3 Years | 135.81% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 732.30 | -0.25 | 695.17 | 123.70 | 5.92 | 0.96 | 746.56/0.00 | -13.33 | Neutral |
| J&J | 177.18 | -0.49 | 426.52 | 16.89 | 10.49 | 2.88 | 178.99/0.00 | 13.43 | Neutral |
| AbbVie | 207.90 | -0.08 | 366.95 | 17.44 | 11.92 | 4.39 | 210.41/0.00 | 7.73 | Bearish |
| Abbott | 131.38 | -0.06 | 227.99 | 30.70 | 4.28 | 1.87 | 131.66/0.00 | 0.58 | Bearish |
| Merck | 81.45 | -1.64 | 206.68 | 26.36 | 3.09 | 2.53 | 85.18/0.00 | -1.89 | Bearish |
Market news
- Stocks finish week higher; Wall Street at record highsSeptember 20, 2025 7:43 AM
- Nasdaq notches record high close, traders look to Fed meetingSeptember 13, 2025 9:16 AM
- Wall Street indexes end lower as jobs data fuels economic worriesSeptember 6, 2025 10:13 AM
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
About the company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.